Great idea as an inaugural use of 'The List". Hope other
Great idea as an inaugural use of 'The List". Hope other chime in.
Seems like I'm in a minority of not buying lately. Don't remember the last time I did. It's been awhile. Mostly because I bill my customer quarterly and try to shove Q3 payment into the next year.
Here's some of my overall thoughts and I have a lot more, but enough to start with...
1.) I do know what it would cost to recreate what Verb has done on the Direct Sales side and with Online Live Shopping. People would ship their pants if they knew. It's a LOT higher than the current market cap not including getting all those customers. What they've created is no 100% guarantee of success, but it does build a nice little moat around it all.
2.) I believe Verb could be profitable soon. I think that would be a BAD mistake for Verb and most tech companies, but it's doable. Keep in mind TalkShopLive isn't burning through cash and could possibly self sustain. You don't need a large team to be successful, but it all depends on how fast you want to grow.
3.) Valuations is another area. I've posted how some of the others were valued at billions, but they won't tell people how many customers they have or sales numbers. There is a reason because it takes time to grow like a lot of other things. But that doesn't stop the high valuations. I would assume they came way down by now. These other companies ARE burning through cash at a record pace 100's of thousands of dollars a year. It's not sustainable now. I anticipating a shakeout unless they can convince some pot committed VCs to through some more money at them.
4.) Verb built the best solution in the industry hands down. There no debating that.
5.) Total revenue for the year might be around $9M-$10M. Market Cap is what, $17M. If someone things the sp is going to zero, they are more nuts then a fruit cake.
6.) Verb is a potential buyout target. You've heard how TikTok and Facebook gave up and it wasn't for a lack of trying. It's every hard to do and Verb has done it. What would it be worth to a large company to own this technology and even better, the customer base with Direct Sales
6.) Haters, biters, snakes and liars. They wouldn't even bother with VERB unless there was value and opportunity. Otherwise they'd be pumping some $0.0001 stock like their job requires. They aren't here because they are in love with me either. Their desperation for attention and creating dozens of IDs is very telling.
11
1
TON Strategy Co. (TONX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...
Continue Reading
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...
Continue Reading
The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...
Continue Reading
Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...
Continue Reading
Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...
Continue Reading
Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...
Continue Reading
Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...
Continue Reading
Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...
Continue Reading
Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...
Continue Reading
Top 5 Most Recently Viewed Articles
U.S. GoldMining Champions Alaska's Development Efforts U.S. GoldMining Inc. (NASDAQ: USGO) expresses strong support for Alaska's recent push to enhance its critical road infrastructure. This initiative, led by the Alaska Industrial Development and Export Authority (AIDEA), is set to significantly improve access to the Whistler Gold-Copper Project. The proposed West...
Continue Reading
New StorageMart Facility Unveiled in Brighton StorageMart, a distinguished name in the self-storage industry, has recently opened a new facility on Wellington Road in Brighton. This latest development marks an exciting chapter of revitalization, successfully blending the site's historic charm with contemporary storage solutions that the community can rely on. A Tribute to...
Continue Reading
374Water Welcomes New Investor Relations Leader 374Water Inc. has made a significant strategic move by appointing Jim Siccardi as the Senior Vice President of Investor Relations. With an impressive background in enhancing shareholder value and building robust investor relations strategies, Siccardi is expected to boost the company's communication strategies within capital...
Continue Reading
BOC Aviation Expands Fleet with 50 Boeing 737-8 Aircraft BOC Aviation has recently enhanced its fleet by placing a firm order for 50 Boeing 737-8 jets, significantly boosting its existing portfolio. This latest acquisition expands the company's 737 MAX collection to a total of 215 aircraft, which includes both 737-8s and 737-9s. With this order, BOC Aviation will have a...
Continue Reading
Bluebird Bio's Stock Hits Record Low: A Closer Look Bluebird bio Inc has recently experienced a dramatic downturn in its stock performance, plummeting to a noteworthy 52-week low of $0.46. This decline represents a staggering reduction of approximately 84.68% over the course of a year, revealing the mounting difficulties the biotech company is grappling with. Investor...
Continue Reading